云计算被广泛认为是信息技术发展的必然趋势。然而,由于在云计算模式下用户失去了对托管在云端的数据和应用的直接控制能力,产生了云服务的可信性问题,严重影响了云计算与云服务的推广。文章设计实现了一种新的通过可信第三方TTP(Truste...云计算被广泛认为是信息技术发展的必然趋势。然而,由于在云计算模式下用户失去了对托管在云端的数据和应用的直接控制能力,产生了云服务的可信性问题,严重影响了云计算与云服务的推广。文章设计实现了一种新的通过可信第三方TTP(Trusted Third Party)对云提供商可信性进行审计和验证的模型。为了防止TTP成为单点瓶颈或单点故障,通过云计算技术构建TTP云验证平台实现了原型系统,并对其进行定量测试、分析和评价。实验结果表明,T-YUN在有效验证可信性的同时没有引入过多的额外代价。展开更多
AIM: To evaluate the association between xeroderma pigmentosum group D (XPD), genetic polymorphism Lys751Gln and esophageal cancer risk. METHODS: We searched PubMed up to September 1, 2010 to identify eligible studies...AIM: To evaluate the association between xeroderma pigmentosum group D (XPD), genetic polymorphism Lys751Gln and esophageal cancer risk. METHODS: We searched PubMed up to September 1, 2010 to identify eligible studies. A total of 10 casecontrol studies including 2288 cases and 4096 controls were included in the meta-analysis. Statistical analysis was performed with Review Manage version 4.2. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.RESULTS: The results suggested that there is no significant association between XPD Lys751Gln polymorphism and esophageal cancer susceptibility in the overall population. However, in subgroup analysis by histology type, a significant association was found between XPD Lys751Gln polymorphism and esophageal adenocarcinoma (for CC vs AA: OR = 1.25, 95% CI = 1.01-1.55, P = 0.05 for heterogeneity). CONCLUSION: Our meta-analysis suggested that XPD Lys751Gln polymorphism may be associated with increased risk of esophageal adenocarcinoma.展开更多
文摘云计算被广泛认为是信息技术发展的必然趋势。然而,由于在云计算模式下用户失去了对托管在云端的数据和应用的直接控制能力,产生了云服务的可信性问题,严重影响了云计算与云服务的推广。文章设计实现了一种新的通过可信第三方TTP(Trusted Third Party)对云提供商可信性进行审计和验证的模型。为了防止TTP成为单点瓶颈或单点故障,通过云计算技术构建TTP云验证平台实现了原型系统,并对其进行定量测试、分析和评价。实验结果表明,T-YUN在有效验证可信性的同时没有引入过多的额外代价。
文摘AIM: To evaluate the association between xeroderma pigmentosum group D (XPD), genetic polymorphism Lys751Gln and esophageal cancer risk. METHODS: We searched PubMed up to September 1, 2010 to identify eligible studies. A total of 10 casecontrol studies including 2288 cases and 4096 controls were included in the meta-analysis. Statistical analysis was performed with Review Manage version 4.2. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.RESULTS: The results suggested that there is no significant association between XPD Lys751Gln polymorphism and esophageal cancer susceptibility in the overall population. However, in subgroup analysis by histology type, a significant association was found between XPD Lys751Gln polymorphism and esophageal adenocarcinoma (for CC vs AA: OR = 1.25, 95% CI = 1.01-1.55, P = 0.05 for heterogeneity). CONCLUSION: Our meta-analysis suggested that XPD Lys751Gln polymorphism may be associated with increased risk of esophageal adenocarcinoma.
